恒瑞医药(01276)自主研发的创新型抗肿瘤药物HRS-2329 片获批开展临床试验

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-2329 tablets, an innovative anti-tumor drug developed by the company [1] Group 1: Product Development - HRS-2329 tablets are designed to treat advanced solid tumors with RAS mutations or amplifications [1] - The drug has shown promising anti-tumor activity in preclinical animal models [1] - Currently, there are no similar drugs approved for sale in both domestic and international markets [1] Group 2: Financial Investment - The total research and development investment for the HRS-2329 project has reached approximately 60.15 million yuan [1]